EDAP management highlighted what it sees as a growing global opportunity for therapeutic ultrasound in urology, emphasizing the company’s Focal One robotic high-intensity focused ultrasound (HIFU) ...
EDAP TMS SA announced the successful treatment of the first patient in its phase I/II PULS Trial, which is investigating the use of High Intensity Focused Ultrasound (HIFU) technology for pancreatic ...
LYON, France, October 1, 2024 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, today announced that the first patients have been treated in a Phase I/II study evaluating the ...
Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the HIFU-treated arm versus 86.2% in patients who underwent radical prostatectomy ...
Treatment with robotic HIFU showed reduction in moderate and severe post-operative complications and reduced hospital stay compared to surgery LYON, France, November 19, 2024 - EDAP TMS SA (Nasdaq: ...
One of the most common concerns about treating prostate cancer is preserving sexual function and urinary control. For some prostate cancers, newer treatments offering an alternative to radiation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results